X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (16) 16
humans (15) 15
index medicus (15) 15
female (14) 14
cancer (11) 11
middle aged (9) 9
ovarian cancer (8) 8
aged (7) 7
ovarian neoplasms - pathology (6) 6
research (6) 6
adult (5) 5
chemotherapy (5) 5
ovarian neoplasms - drug therapy (5) 5
ovarian neoplasms - genetics (5) 5
breast-cancer (4) 4
care and treatment (4) 4
genetics (4) 4
obstetrics & gynecology (4) 4
ovarian neoplasms - metabolism (4) 4
tumors (4) 4
aged, 80 and over (3) 3
analysis (3) 3
biomarkers (3) 3
cancer research (3) 3
carcinoma, ovarian epithelial (3) 3
carcinoma, squamous cell - pathology (3) 3
cell line, tumor (3) 3
dna repair (3) 3
drug therapy (3) 3
gene expression (3) 3
growth-factor receptor (3) 3
gynecologic-oncology-group (3) 3
hematology, oncology and palliative medicine (3) 3
medical research (3) 3
mutation (3) 3
neoplasm proteins - genetics (3) 3
neoplasms, glandular and epithelial - drug therapy (3) 3
neoplasms, glandular and epithelial - pathology (3) 3
neoplasms. tumors. oncology. including cancer and carcinogens (3) 3
pathway (3) 3
poly polymerase (3) 3
signal transduction (3) 3
survival (3) 3
treatment outcome (3) 3
antineoplastic agents - pharmacology (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
apoptosis (2) 2
brca1 (2) 2
breast cancer (2) 2
cancer therapies (2) 2
carcinoma (2) 2
carcinoma, squamous cell - genetics (2) 2
carcinoma, squamous cell - virology (2) 2
cell lung-cancer (2) 2
cytotoxicity (2) 2
deoxyribonucleic acid--dna (2) 2
disease-free survival (2) 2
endocrine system diseases (2) 2
epidermal growth factor (2) 2
expression (2) 2
female genital diseases and pregnancy complications (2) 2
gene expression profiling (2) 2
gene expression regulation, neoplastic (2) 2
gene-expression (2) 2
genetic aspects (2) 2
genomic instability (2) 2
head and neck neoplasms - pathology (2) 2
health aspects (2) 2
health sciences, oncology (2) 2
hmg-coa reductase (2) 2
hpv (2) 2
human papillomavirus (2) 2
human-papillomavirus (2) 2
intraepithelial neoplasia (2) 2
lovastatin-induced apoptosis (2) 2
molecular targeted therapy - methods (2) 2
neoplasms, glandular and epithelial - genetics (2) 2
neoplasms, glandular and epithelial - metabolism (2) 2
obstetrics and gynecology (2) 2
online only (2) 2
ovarian carcinoma (2) 2
ovarian neoplasms - mortality (2) 2
ovarian neoplasms - therapy (2) 2
papillomaviridae - pathogenicity (2) 2
papillomavirus infections - virology (2) 2
patients (2) 2
phase-ii (2) 2
phase-ii trial (2) 2
platinum-based chemotherapy (2) 2
prognosis (2) 2
research article (2) 2
risk (2) 2
skin and connective tissue diseases (2) 2
squamous-cell carcinoma (2) 2
trial (2) 2
vulvar neoplasms - genetics (2) 2
vulvar neoplasms - pathology (2) 2
vulvar neoplasms - virology (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Coleman, Robert L and Coleman, R L and Oza, Amit M and Oza, A M and Lorusso, D and Lorusso, Domenica and Aghajanian, C and Aghajanian, Carol and Oaknin, A and Oaknin, Ana and Dean, A and Dean, Andrew and Colombo, N and Colombo, Nicoletta and Weberpals, Johanne I and Weberpals, J I and Clamp, Andrew and Clamp, A and Scambia, Giovanni and Scambia, G and Leary, A and Leary, Alexandra and Holloway, Robert W and Holloway, R W and Gancedo, M Amenedo and Gancedo, Margarita Amenedo and Fong, Peter C and Fong, P C and Goh, Jeffrey C and Goh, J C and O'Malley, David M and O'Malley, D M and Armstrong, Deborah K and Armstrong, D K and Garcia-Donas, Jesus and Garcia-Donas, J and Swisher, E M and Swisher, Elizabeth M and Floquet, A and Floquet, Anne and Konecny, Gottfried E and Konecny, G E and McNeish, I A and McNeish, Iain A and Scott, C L and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, J A and Ledermann, Jonathan A and Buck, M and Friedlander, M L and Harnett, P and Kichenadasse, G and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Plante, M and Provencher, D and Welch, S and Gladieff, L and Joly, F and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Pignata, S and Sabbatini, R F and Tamberi, S and Zamagni, C and O'Donnell, A and Herraez, A Casado and Guerra, E M and Palacio, I and Romero, I and Sanchez, A and ... and ARIEL3 Investigators and ARIEL3 investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | ADP | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum
Journal Article
2005, ISBN 0494022396
The BRCA1 protein is involved in the cellular response to DNA repair and has an essential role in the maintenance of genomic stability, and the inactivation of... 
Health Sciences, Oncology
eBook
2005, ISBN 0494022396
The BRCA1 protein is involved in the cellular response to DNA repair and has an essential role in the maintenance of genomic stability, and the inactivation of... 
Health Sciences, Oncology
eBook
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4501 - 4510
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2008, Volume 26, Issue 19, pp. 3259 - 3267
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 2016, Volume 14, Issue 1, p. 83
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2018, Volume 24, Issue 24, pp. 6168 - 6174
Purpose: Patients with recurrent ovarian clear cell carcinoma (OCCC) have limited effective options due to chemoresistance. A phase II study was designed to... 
SURVIVAL | ONCOLOGY | RECURRENT | AURORA KINASES | ADENOCARCINOMA | THERAPEUTIC TARGET | PTEN | MUTATIONS | ARID1A | CANCER | EXPRESSION
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 137, Issue 2, pp. 216 - 222
Journal Article
Journal Article
Journal Article
Cancer Cell International, ISSN 1475-2867, 08/2011, Volume 11, Issue 1, pp. 29 - 29
Background: The inhibition of Breast Cancer 1 (BRCA1) expression sensitizes breast and ovarian cancer cells to platinum chemotherapy. However, therapeutically... 
GAMMA-H2AX FOCI | GYNECOLOGIC-ONCOLOGY-GROUP | ONCOLOGY | SUBEROYLANILIDE HYDROXAMIC ACID | DOUBLE-STRAND BREAKS | PHASE-II | TUMOR-CELLS | PROGNOSTIC-SIGNIFICANCE | DNA-REPAIR | VORINOSTAT | HUMAN ENDOMETRIAL | Antimitotic agents | Cancer cells | Physiological aspects | Breast cancer | Diagnosis |